29A Stock Overview
A bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France.
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 3/6 |
| Past Performance | 6/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Amphastar Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$40.56 |
| 52 Week High | US$58.50 |
| 52 Week Low | US$34.10 |
| Beta | 0.83 |
| 11 Month Change | 1.76% |
| 3 Month Change | 10.04% |
| 1 Year Change | -14.43% |
| 33 Year Change | 168.61% |
| 5 Year Change | 109.29% |
| Change since IPO | 286.21% |
Recent News & Updates
Recent updates
Shareholder Returns
| 29A | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -7.1% | -2.0% | -3.0% |
| 1Y | -14.4% | -16.0% | 4.0% |
Return vs Industry: 29A exceeded the German Pharmaceuticals industry which returned -16% over the past year.
Return vs Market: 29A underperformed the German Market which returned 4% over the past year.
Price Volatility
| 29A volatility | |
|---|---|
| 29A Average Weekly Movement | 5.1% |
| Pharmaceuticals Industry Average Movement | 5.3% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.7% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 29A has not had significant price volatility in the past 3 months.
Volatility Over Time: 29A's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 1,761 | Jack Zhang | www.amphastar.com |
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures.
Amphastar Pharmaceuticals, Inc. Fundamentals Summary
| 29A fundamental statistics | |
|---|---|
| Market cap | €1.99b |
| Earnings (TTM) | €150.18m |
| Revenue (TTM) | €642.96m |
13.3x
P/E Ratio3.1x
P/S RatioIs 29A overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 29A income statement (TTM) | |
|---|---|
| Revenue | US$712.89m |
| Cost of Revenue | US$320.38m |
| Gross Profit | US$392.51m |
| Other Expenses | US$225.99m |
| Earnings | US$166.52m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 3.42 |
| Gross Margin | 55.06% |
| Net Profit Margin | 23.36% |
| Debt/Equity Ratio | 82.2% |
How did 29A perform over the long term?
See historical performance and comparison